TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Pharmaust Limited ( (AU:NUZ) ).
Neurizon Therapeutics Limited has announced the commencement of trading on the OTCQB Venture Market in the U.S., which is expected to increase liquidity and visibility in the international market. This move is part of Neurizon’s broader strategy to expand its presence in North American capital markets, facilitated by its partnership with Integrous Communications. The company is entering a pivotal phase with its lead drug candidate, NUZ-001, as it prepares to initiate the HEALEY ALS Platform Trial, potentially accelerating the path to regulatory approval and commercialization.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is aimed at treating Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease. The company is committed to accelerating access to effective ALS treatments and exploring broader applications for NUZ-001.
Average Trading Volume: 575,615
Technical Sentiment Signal: Hold
Current Market Cap: A$82.86M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.